Incyte (INCY) Share-based Compensation (2010 - 2026)
Incyte's (INCY) quarterly Share-based Compensation came in at $67.3 million in Q2 2026, up 4.11% YoY from $64.6 million in Q2 2025, and up 4.89% on a QoQ basis from $64.1 million in Q1 2026.
Incyte (INCY) Share-based Compensation (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Share-based Compensation data on file, last reported at $67.3 million in Q2 2026.
- Quarterly Share-based Compensation rose 4.11% year-over-year to $67.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $255.1 million (down 7.3% YoY) and the FY2025 annual result came in at $249.3 million, down 6.28% from the prior year.
- Share-based Compensation rose to $67.3 million in Q2 2026, from $64.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $77.9 million in Q3 2024 to a low of $43.8 million in Q1 2022.
- A 5-year average of $58.4 million and a median of $59.9 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 118.9% — and 2025, when it slipped 20.95%.
- Tracing INCY's Share-based Compensation over 5 years: stood at $52.7 million in 2022, then rose by 13.88% to $60.0 million in 2023, then gained by 19.55% to $71.7 million in 2024, then fell by 13.33% to $62.2 million in 2025, then advanced by 8.21% to $67.3 million in 2026.
- The last three Share-based Compensation figures came in at $67.3 million (Q2 2026), $64.1 million (Q1 2026), and $62.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 67.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.26 Mn |
| Jun 30, 2026 | 67.26 Mn |
| Mar 31, 2026 | 64.13 Mn |
| Mar 31, 2026 | 64.13 Mn |
| Dec 31, 2025 | 62.16 Mn |
| Dec 31, 2025 | 62.16 Mn |
| Sep 30, 2025 | 61.60 Mn |
| Sep 30, 2025 | 61.60 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Dec 31, 2024 | 71.72 Mn |
| Dec 31, 2024 | 71.72 Mn |
| Sep 30, 2024 | 77.92 Mn |
| Sep 30, 2024 | 77.92 Mn |
| Jun 30, 2024 | 56.64 Mn |
| Jun 30, 2024 | 56.64 Mn |
| Mar 31, 2024 | 59.78 Mn |
| Mar 31, 2024 | 59.78 Mn |